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9.1: For the following infection-related GN, we suggest
appropriate treatment of the infectious disease and
standard approaches to management of the kidney
manifestations: (2D)
K poststreptococcal GN;
K infective endocarditis-related GN;
K shunt nephritis.
INTRODUCTION
This chapter provides recommendations for the treatment
of infection-associated GN, which may occur in association
with bacterial, viral, fungal, protozoal, and helminthic
infection (Table 21). The cost implications for global
application of this guideline are addressed in Chapter 2.
BACTERIAL INFECTION–RELATED GN
BACKGROUND AND RATIONALE
The prototype for bacterial infection-related GN (also called
postinfectious GN) is poststreptococcal GN, which most
often occurs in children following a pharyngeal or cutaneous
infection (impetigo) caused by a particular nephritogenic
strain of Streptococci, and usually has a favorable outcome.
However, in the last decades the spectrum of postinfec-
tious GN has changed. The incidence of poststreptococcal
GN, particularly in its epidemic form, has progressively
declined in industrialized countries. Recent series reported
that streptococcal infections accounted for only 28–47% of
acute GN, Staphylococcus aureus or Staphylococcus epidermidis
being isolated in 12–24% of cases and Gram-negative bacteria
in up to 22% of cases.330–332 Bacterial endocarditis and shunt
infections are also frequently associated with postinfectious
GN. Moreover, the atypical postinfectious GN tends to affect
mainly adults who are immunocompromised, e.g., in
association with alcoholism, diabetes, and drug addiction.
While spontaneous recovery within a few weeks is still the
rule in children affected by the typical poststreptococcal GN,
the prognosis in immunocompromised adults with post-
infectious GN is significantly worse, with less than 50% in
complete remission after a long follow-up.333
POSTSTREPTOCOCCAL GN
BACKGROUND AND RATIONALE
The diagnosis of poststreptococcal GN requires the demon-
stration of antecedent streptococcal infection in a patient
who presents with acute GN. Nephritis may follow 7–15 days
after streptococcal tonsillitis and 4–6 weeks after impetigo.334
The nature of the nephritogenic streptococcal antigen is
still controversial.334–336 Kidney biopsy is not indicated unless
there are characteristics that make the diagnosis doubtful, or
to assess prognosis and/or for potential therapeutic reasons.
The kidney histology shows acute endocapillary GN with
mesangial and capillary granular immune deposition.
The clinical manifestations of acute nephritic syndrome
usually last less than 2 weeks. Less than 4% of children with
poststreptococcal GN have massive proteinuria, and occa-
sionally a patient develops crescentic GN with rapidly
progressive kidney dysfunction. Serum C3 values usually
return to normal by 8–10 weeks after recognition of the
infection. Persistent hypocomplementemia beyond 3 months
may be an indication for a renal biopsy, if one has not already
been performed. A lesion of MPGN is commonly found in
persistently hypocomplementemic GN.
The short-term prognosis of the acute phase of post-
streptococcal GN is excellent in children; however, in elderly
patients, mortality in some series is as high as 20%. Although
the long-term prognosis of poststreptococcal GN is debated,
the incidence of ESRD in studies with 15 years of follow-up
is less than 1%, with the exception being that long-term
prognosis is poor in elderly patients who develop persistent
proteinuria.333,334
Well-documented streptococcal infection should be trea-
ted with penicillin, or erythromycin if the patient is allergic
to penicillin, to resolve streptococcal infection and prevent
the spread of the nephritogenic streptococcus among relatives
or contacts. However, antibiotics are of little help for
reversing GN, as the glomerular lesions induced by immune
complexes are already established.
The management of acute nephritic syndrome, mainly in
adults, requires hospital admission if features of severe hyper-
tension or congestive heart failure are present. Hypertension
and edema usually subside after diuresis is established. Adult
patients persisting with urinary abnormalities beyond
6 months, especially if proteinuria 41 g/d, should receive
ACE-I or ARBs, as in other proteinuric glomerular diseases (see
Chapter 2). The long-term prognosis is worse in patients, mainly
adults, who have persistent proteinuria after 6 months.337
Pulses of i.v. methylprednisolone can be considered in
patients with extensive glomerular crescents and rapidly progres-
sive GN, based on extrapolation from other rapidly progressive
and crescentic GNs, although there is no evidence from RCTs.
RESEARCH RECOMMENDATIONS
K An RCT is needed to evaluate the treatment of crescentic
poststreptococcal GN with corticosteroids.
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K Research is needed to determine the nature of the
streptococcal antigen, as a basis for developing immuno-
prophylactic therapy.
GN ASSOCIATED WITH INFECTIVE ENDOCARDITIS
BACKGROUND AND RATIONALE
The natural history of GN associated with infective endocarditis
has been significantly altered with the changing epidemiology of
the disorder, and with the use of antibiotics.337–340
In USA, infective endocarditis is diagnosed in approxi-
mately 40 cases per million every year, and the disease is
increasingly frequent in elderly individuals and in patients
with no underlying heart disease. i.v. drug usage, prosthetic
heart valves, and structural heart disease are risk factors.
Staphylococcus aureus has replaced Streptococcus viridans as
the leading cause of infective endocarditis. The incidence of
GN associated with Staphylococcus aureus endocarditis ranges
from 22% to 78%, the highest risk being among i.v. drug
users. Focal and segmental proliferative GN, often with focal
crescents, is the most typical finding. Some patients may
exhibit a more diffuse proliferative endocapillary lesion with
or without crescents.337–340
The immediate prognosis of the GN is good, and is related
to the prompt eradication of the infection, using appropriate
antibiotics for 4–6 weeks.
RESEARCH RECOMMENDATION
K Multicenter studies are needed to determine the in-
cidence, prevalence, and long-term prognosis of infective
endocarditis–related GN.
SHUNT NEPHRITIS
BACKGROUND AND RATIONALE
Shunt nephritis is an immune complex–mediated GN that
develops as a complication of chronic infection on ventricu-
loatrial or ventriculojugular shunts inserted for the treatment
of hydrocephalus.341
The diagnosis is based on clinical evidence of kidney disease
(most commonly, microscopic hematuria and proteinuria,
frequently in the nephrotic range, occasionally elevated SCr
and hypertension) with prolonged fever or signs of chronic
infection, in a patient with a ventriculovascular shunt implanted
for treatment of hydrocephalus. The histologic findings are
typically type 1 MPGN, with granular deposits of IgG, IgM, and
C3, and electron-dense mesangial and subendothelial deposits.
The renal outcome of shunt nephritis is good if there is early
diagnosis and treatment of the infection. Ventriculovascular shunts
may become infected in about 30% of cases. GN may develop in
0.7–2% of the infected ventriculovascular shunts in an interval of
time ranging from 2 months to many years after insertion. The
infecting organisms are usually Staphylococcus epidermidis or
Staphylococcus aureus. In contrast to ventriculovascular shunts,
ventriculoperitoneal shunts are rarely complicated with GN.
A late diagnosis, resulting in delays in initiating antibiotic
therapy and in removing the shunt, results in a worse renal
prognosis.
RESEARCH RECOMMENDATION
K Multicenter observational studies are needed to deter-
mine the incidence, prevalence, and long-term prognosis
of shunt nephritis.
Table 21 | Infections associated with glomerulonephritis
Bacterial Viral
Mycobacterium leprae, M. tuberculosis Hepatitis B and C
Treponema pallidum Human immunodeficiency virus
Salmonella typhi, S. paratyphi, S. typhimurium Epstein-Barr virus
Streptococcus pneumoniae, S. virdans, S. pyogenes Coxsackie B
Staphyloccoccus aureus, S. epidermidis, S. albus ECHO virus
Leptospira speciesa Cytomegalovirus
Yersinia enterocoliticaa Varicella zoster
Neisseria meningitidis, Neisseria gonorrhoeaea Mumps
Corynebacterium diphtheriaea Rubella
Coxiella burnettiia Influenza
Brucella abortusa
Listeria monocytogenesa
Fungal Helminthic
Histoplasma capsulatuma Schistosoma mansoni, S. japonicum, S. haematobium
Candidaa Wuchereria bancrofti
Coccidiodes immitisa Brugia malayi
Loa loa
Protozoal Onchocerca volvulus
Plasmodium malariae, P. falciparum Trichinella spiralisa
Leishmania donovani
Toxoplasma gondii
Trypanosoma cruzi, T. bruci
Toxocara canisa
Strongyloides stercoralisa
ECHO, enteric cytopathic human orphan; GN, glomerulonephritis.
aOnly case reports documented.
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9.2: Hepatitis C virus (HCV) infection–related GN
(Please also refer to the published KDIGO Clinical Practice
Guidelines for the Prevention, Diagnosis, Evaluation, and
Treatment of Hepatitis C in Chronic Kidney Disease.342)
9.2.1: For HCV-infected patients with CKD Stages 1
or 2 and GN, we suggest combined antiviral
treatment using pegylated interferon and riba-
virin as in the general population. (2C) [based
on KDIGO HCV Recommendation 2.2.1]
9.2.1.1: Titrate ribavirin dose according to
patient tolerance and level of renal
function. (Not Graded)
9.2.2: For HCV-infected patients with CKD Stages 3,
4, or 5 and GN not yet on dialysis, we suggest
monotherapy with pegylated interferon, with
doses adjusted to the level of kidney function.
(2D) [based on KDIGO HCV Recommendation
2.2.2]
9.2.3: For patients with HCV and mixed cryoglobuli-
nemia (IgG/IgM) with nephrotic proteinuria or
evidence of progressive kidney disease or an
acute flare of cryoglobulinemia, we suggest either
plasmapheresis, rituximab, or cyclophospha-
mide, in conjunction with i.v. methylpredniso-
lone, and concomitant antiviral therapy. (2D)
BACKGROUND
HCV infection is a major public health problem, with an
estimated 130–170 million people infected worldwide.343–345
HCV frequently causes extrahepatic manifestations, includ-
ing mixed cryoglobulinemia, lymphoproliferative disorders,
Sjo¨gren’s syndrome, and kidney disease. A major concern is
the lack of safe and effective drugs to treat HCV-infected
patients with CKD.346 Unfortunately, there are no large-scale
clinical trials in patients with HCV-associated kidney disease;
thus, evidence-based treatment recommendations cannot be
made in this patient population. However, we have extra-
polated HCV treatment from the non-CKD population, with
the appropriate and necessary dose adjustments.
Kidney involvement due to HCV is most commonly
associated with type II cryoglobulinemia, and is clinically
manifested by proteinuria, microscopic hematuria, hyperten-
sion, and mild to moderate kidney impairment.347,348
On kidney biopsy, a type I MPGN pattern of injury is the
most common pathological finding.349 Vasculitis of the
small- and medium-sized renal arteries can also be present.
Immunofluorescence usually demonstrates deposition of
IgM, IgG, and C3 in the mesangium and capillary walls.
On electron microscopy, subendothelial immune complexes
are usually seen and may have an organized substructure
suggestive of cryoglobulin deposits.348,350 Besides MPGN,
other forms of glomerular disease have been described in
patients with HCV, including IgAN, MN, postinfectious GN,
thrombotic microangiopathies, FSGS, and fibrillary and
immunotactoid GN.348–354
Patients with type II cryoglobulinemia (mixed polyclonal
IgG and monoclonal IgM [Rheumatoid-factor positive]
cryoglobulins) should be tested for HCV. Patients with
proteinuria and cryoglobulinemia should be tested for HCV
RNA even in the absence of clinical and/or biochemical
evidence of liver disease. Similarly, HCV-infected patients
should be tested at least annually for proteinuria, hematuria,
and eGFR to detect possible HCV-associated kidney disease.
Practice guidelines for treatment of HCV infection in general
have been recently published.355 For detailed information
regarding treatment of HCV-mediated kidney disease the
reader is also referred to the recently published KDIGO Clinical
Practice Guidelines for the Prevention, Diagnosis, Evaluation,
and Treatment of Hepatitis C in Chronic Kidney Disease.342
RATIONALE
K There is low-quality evidence to recommend treatment of
HCV-associated GN. Treatment should be focused on
reducing or eliminating HCV replication, and reducing
the formation and glomerular deposition of HCV-
containing immune complexes (including cryoglobulins).
K There is low-quality evidence to recommend dose
adjustments for interferon and ribavirin based on level
of kidney function.
K There is very low–quality evidence to suggest that patients
with HCV-associated GN and severe kidney manifesta-
tions require additional treatment with immunosuppres-
sion and/or corticosteroids and/ or plasma exchange.
The best long-term prognostic indicator of HCV-asso-
ciated GN is sustained virologic response (defined as HCV
RNA clearance from serum) for at least 6 months after
cessation of therapy. In patients with normal kidney
function, this aim can be best achieved by the use of
pegylated interferon-a-2a/2b in combination with ribavirin,
which results in sustained virological response rates of
45–50% in genotypes 1 and 4, and 70–80% in genotypes
2 and 3 in HVC-monoinfected patients. This represents the
current standard of care for HCV infection.342,355
Treatment regimens for HCV-associated GN and the doses
of individual agents will vary with the severity of the kidney
disease. No dose adjustment is needed for patients with eGFR
460 ml/min.356–358
There is a paucity of information regarding treatment of HCV-
infected patients with GFR o60 ml/min but not yet on dialysis
(CKD stages 3–5). The suggested doses (based on expert opinion,
not evidence) are pegylated interferon-a-2b, 1mg/kg subcuta-
neously once weekly or pegylated interferon-a-2a, 135mg sub-
cutaneously once weekly, together with ribavirin 200–800 mg/d in
two divided doses, starting with the low dose and increasing
gradually, as long as side-effects are minimal and manageable (see
Table 22). Hemolysis secondary to ribavirin very commonly limits
its dosage or prevents its use in patients with CKD.
Monotherapy with interferon-a has been used in cryo-
globulinemic GN with complete clearance of HCV RNA and
improved kidney function; however, recurrence of viremia
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and relapses of kidney disease were universally observed
after interferon was discontinued.359,360 Subsequent studies
with interferon-a monotherapy360–363 have yielded mixed
results.360 Treatment with interferon-a may exacerbate
cryoglobulinemic vasculitis.364,365 Thus, it is recommended
that interferon -a should be started after the acute flare has
been controlled with immunosuppressive agents.366
Better outcomes have been achieved by combined use of
interferon-a with ribavirin367–370 and pegylated interferon with
ribavirin.366,370–374 In a recent meta-analysis of controlled
clinical trials comparing the efficacy and safety of antiviral vs.
immunosuppressive therapy (corticosteroids alone or in
combination with cyclophosphamide) in patients with HCV-
associated GN, proteinuria decreased more (odds ratio 3.86)
after interferon therapy (3 MU thrice weekly for at least 6
months).375 However, both treatments failed to significantly
improve kidney function. Recently published KDIGO guidelines
for treatment of viral hepatitis in patients with kidney disease
suggest that patients with moderate proteinuria and slowly
progressive kidney disease can be treated with a 12-month
course of standard interferon-a or pegylated interferon-a-2a
with dose adjusted as described below plus ribavirin, with or
without erythropoietin support, depending on the level of
hemoglobin.342 Ribavirin dose needs to be titrated according to
patient tolerance; caution is advised for patients with clearance
o50 ml/min which may require substantially reduced dosage.
There is very low–quality evidence that patients with
nephrotic-range proteinuria and/or rapidly progressive
kidney failure or an acute flare of cryoglobulinemia, should
receive additional therapy with either plasmapheresis (3 L of
plasma thrice weekly for 2–3 weeks), rituximab (375 mg/m2
once a week for 4 weeks), or cyclophosphamide (2 mg/kg/d
for 2–4 months) plus i.v. methylprednisolone 0.5–1 g/d for
3 days.342 There are no comparative data to favour any one of
these three additional therapies. Corticosteroids may lead to
increases in HCV viral load.376,377
Case reports have suggested remarkable reduction in
proteinuria and stabilization of kidney function in
response to rituximab in patients with cryoglobulinemic
vasculitis.378,379 Although HCV viremia increased modestly
in some patients, it remained unchanged or decreased in
others and the overall treatment was considered safe.380
Observations in 16 patients with severe refractory HCV-
related cryoglobulinemia vasculitis treated with rituximab in
combination with pegylated interferon-a-2b and ribavirin
also showed good response.381 Symptoms usually reappear
with reconstitution of peripheral B cells. The long-term safety
of multiple courses of rituximab in patients with HCV is
unknown. It remains debatable whether antiviral therapy
should be commenced as soon as immunosuppression is
begun or delayed until a clinical remission (complete or
partial) is evident.382–384
There is a paucity of controlled studies available in HCV-
associated GN; most studies are retrospective analyses with
small sample sizes. Most of the available evidence comes from
studies of patients with significant proteinuria, hematuria, or
reduced kidney function.
RESEARCH RECOMMENDATIONS
K Epidemiologic studies are needed to determine:
J the prevalence and types of glomerular lesions in
HCV-infected patients;
J whether there are true associations between HCV
infection and GN other than MPGN (e.g., IgAN).
K An RCT is needed to evaluate corticosteroids plus
cyclophosphamide in addition to antiviral therapy in
HCV-associated GN.
K An RCT is needed to evaluate rituximab in addition to
antiviral therapy in HCV-associated GN.
9.3: Hepatitis B virus (HBV) infection–related GN
9.3.1: We recommend that patients with HBV
infection and GN receive treatment with
interferon-a or with nucleoside analogues as
recommended for the general population by
standard clinical practice guidelines for HBV
infection (see Table 23). (1C)
9.3.2: We recommend that the dosing of these
antiviral agents be adjusted to the degree of
kidney function. (1C)
BACKGROUND
Approximately one-third of the world’s population has
serological evidence of past or present infection with HBV,
and 350 million people are chronically infected, making
it one of the most common human pathogens.385,386 The
spectrum of disease and natural history of chronic HBV
infection is diverse and variable, ranging from a low viremic
inactive carrier state to progressive chronic hepatitis, which
may evolve to cirrhosis and hepatocellular carcinoma. It is
not possible to predict which patients with HBV infection are
more likely to develop kidney disease.387
Table 22 | Treatment of HCV infection according to stages of
CKD
Stages of
CKD IFNa Ribavirinb
1 and 2
Pegylated IFNa-2a: 180mg SQ q wk 800–1200mg/d in
Pegylated IFNa-2b: 1.5 mg/kg SQ q wk two divided doses
3 and 4
Pegylated IFNa-2a: 135mg SQ q wk
*Pegylated IFNa-2b: 1 mg/kg SQ q wk
5
Pegylated IFNa-2a: 135mg SQ q wk
*Pegylated IFNa-2b: 1 mg/kg SQ q wk
eGFR, estimated glomerular filtration rate; IFN, interferon; SQ, subcutaneous; q wk,
every week.
aPatients with genotypes 1 and 4 should receive 48 weeks of IFN therapy if an early
viral response is obtained at 12 weeks (42 log fall in viral titer). Genotypes 2 and 3
should be treated for 24 weeks.
bPatients with genotypes 2 and 3 infection should receive 800mg/d with Stages 1
and 2 CKD. Patients infected with genotypes 1 and 4 should receive 1000–1200mg/d
with Stages 1 and 2 CKD.
*Since the publication of KDIGO Hepatitis C in CKD guideline,342 product label
changes now permit concurrent use of ribavirin in patients with CKD Stages 3–5 as
long as side-effects are minimal and manageable. Caution is advised for patients
with clearance o50ml/min, which may require substantially reduced dosage.
Consult local package inserts for information on dosing modifications.
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HBV-associated patterns of GN include MN, MPGN,
FSGS and IgAN. MN is the most common form of HBV-
mediated GN, especially in children. The diagnosis of HBV-
mediated GN requires detection of the virus in the blood and
the exclusion of other causes of glomerular disease. In
children, HBV-mediated GN has a favorable prognosis, with
high spontaneous remission rate. In adults, HBV-mediated
GN is usually progressive. Patients with nephrotic syndrome
and abnormal liver function tests have an even worse
prognosis, with 450% progressing to ESRD in the short
term.388 There are no RCT studies on the treatment of HBV-
mediated GN, so evidence-based treatment recommendations
cannot be made. Clinical practice guidelines on the manage-
ment of chronic hepatitis B have been recently published
in Europe and in the USA, but do not include specific
recommendations on HBV-mediated kidney disease.385,386
RATIONALE
K Treatment of HBV-associated GN with interferon or
nucleoside analogues is indicated.
Several drugs are now available for the treatment of
chronic HBV infection (see Table 23). The efficacy of these
drugs has been assessed in an RCT at 1 year (2 years with
telbivudine). Longer follow-up (up to 5 years) is available for
lamivudine, adefovir, entecavir, telbivudine, and tenofovir in
patient subgroups.385 However, there are no data to indicate
the effect of these treatments for HBV infection on the
natural history of HBV-related GN. Treatment of patients
with HBV infection and GN should be conducted according
to standard clinical practice guidelines for HBV infection.
Nephrotoxicity of some of the nucleoside analogues (adefovir
and tenofovir) can be of concern.
The heterogeneity of patients with HBV infection (e.g.,
degree of liver function impairment, extent of extrahepatic
involvement) creates substantial complexity in establishing
treatment guidelines in patients with HBV-mediated kidney
disease.
RESEARCH RECOMMENDATIONS
K RCTs are needed to establish the most effective anti-
viral treatment regimen in modifying the progression of
HBV-associated GN. Studies will need to account for the
extrarenal disease involvement, as well as evaluate varying
drug combinations, including timing and duration of
therapy.
K RCTs in children should be evaluated separately in view
of the higher rate of spontaneous remission in HBV-
associated GN.
9.4: Human Immunodeficiency virus (HIV) infection–
related glomerular disorders
9.4.1: We recommend that antiretroviral therapy
be initiated in all patients with biopsy-proven
HIV-associated nephropathy, regardless of
CD4 count. (1B)
BACKGROUND
Approximately 5 million people a year are infected with HIV
worldwide.390 Kidney disease is a relatively frequent compli-
cation in patients infected with HIV.
Human immunodeficiency virus–associated nephropathy
(HIVAN) is the most common cause of CKD in patients
with HIV-1, and is mostly observed in patients of African
descent,391,392 perhaps related to susceptibility associated
with genetic variation at the APOL1 gene locus on
chromosome 22, closely associated with the MYH9 lo-
cus.164,393 Untreated, HIVAN rapidly progresses to ESRD.
Typical HIVAN pathology includes FSGS, often with a
collapsing pattern, accompanied by microcystic change in
tubules. There are usually many tubuloreticular structures
seen on electron microscopy. In addition to HIVAN, a
number of other HIV-associated kidney diseases have been
described.391,394,395 In patients with HIV, proteinuria and/or
decreased kidney function is associated with increased
mortality and worse outcomes.396 Data from a number of
RCTs suggest that highly active antiretroviral therapy
(HAART) is beneficial in both preservation and improve-
ment of kidney function in patients with HIV.397–399 Patients
with kidney dysfunction at start of HAART have the most
dramatic improvements in kidney function.400,401 A decrease
in HIV viral load during HAART is associated with kidney
function improvement, while an increase in viral load is
associated with worsening kidney function.402–404
Table 23 |Dosage adjustment of drugs for HBV infection according to kidney function (endogenous CrCl)
Drug CrCl 450 (ml/min) 30o CrCl o50 (ml/min) 10o CrCl o30 (ml/min) CrCl o10 (ml/min)
Lamivudine 300mg p.o. q.d. or
150mg p.o. b.i.d.
150mg p.o. q.d. 150mg first dose then
100mg p.o. q.d.a
150mg first dose then
50mg p.o. q.d.b
Adefovir 10mg p.o. q.d. 10mg p.o. every 48 hours 10mg po every 72 hours No dosing recommended
Entecavir 0.5mg p.o. q.d. 0.25mg p.o. q.d. 0.15mg p.o. q.d. 0.05mg p.o. q.d.
Entecavir in lamivudine-
refractory patients
1mg p.o. q.d. 0.5mg p.o. q.d. 0.3mg p.o. q.d. 0.1mg p.o. q.d.
Telbivudine 600mg p.o. q.d. 600mg p.o. every 48 hours 600mg p.o. every 72 hours 600mg p.o. every 96 hours
Tenofovir 300mg p.o. q.d. 300mg p.o. q.d every 48 hours 300mg p.o. q.d every 72–96 hours 300mg p.o. q.w.
b.i.d., twice daily; CrCl, creatinine clearance; HBV, hepatitis B virus; p.o., orally; q.d., every day; q.w., once a week.
aFor CrCl o15ml/min, 150mg first dose, then 50mg p.o. q.d.
bFor CrCl o5ml/min, 50mg first dose, then 25mg p.o. q.d.
Adapted by permission from Macmillan Publishers Ltd: Kidney International. Olsen SK, Brown RS, Jr. Hepatitis B treatment: Lessons for the nephrologist. Kidney Int 2006; 70:
1897–1904;387 accessed http://www.nature.com/ki/journal/v70/n11/pdf/5001908a.pdf. Supplemented with data from ref 389.
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RATIONALE
K There is low-quality evidence to suggest a kidney biopsy
is necessary to define the specific type of kidney diseases
present in patients with HIV infection.
K HAART may be effective in HIVAN, but it is not effective
in other GN associated with HIV infection.
Causes of kidney disease, other than HIVAN, that occur in
patients with HIV infection include diabetic nephropathy,
thrombotic microangiopathies, cryoglobulinemia, immune
complex GN, an SLE-like GN, or amyloidosis (see
Table 24).394,395,405,406 More than a third of the patients with
HIV who underwent a kidney biopsy had diabetic nephro-
pathy; or MN, MPGN, IgAN, or another pattern of immune-
complex GN.395,407 In patients with HIV infection, many of
these pathologies can mimic HIVAN, but each condition
requires a different therapy.391,394,395,408 Studies in HIV-
infected patients with kidney disease from Africa showed a
high prevalence of HIVAN, but other forms of GN and
interstitial nephritis were also present (see Table 24).409,410
Cohen and Kimmel recently reviewed the rationale for a
kidney biopsy in the diagnosis of HIV-associated kidney
disease.391,411
Observational studies and data from uncontrolled or
retrospective studies398,399,412–415 and from an RCT397 suggest
that HAART (defined as combination therapy with three or
more drugs) is beneficial in both preservation and improve-
ment of kidney function in patients with HIVAN. Since the
introduction of HAART in the 1990s, there has also been a
substantial reduction in the incidence of HIVAN.416 In
multivariate analysis, HIVAN risk was reduced by 60% (95%
CI 30% to 80%) by use of HAART, and no patient
developed HIVAN when HAART had been initiated prior
to the development of acquired immune deficiency syn-
drome.416 The use of HAART has also been associated with
improved kidney survival in patients with HIVAN.417
Antiviral therapy has been associated with GFR improve-
ments in HIV patients with both low CD4 lymphocyte counts
and impaired baseline kidney function, supporting an
independent contribution of HIV-1 replication to chronic
kidney dysfunction in advanced HIV disease.398
Early observational studies suggested a benefit for ACE-
I.418 A number of retrospective, observational, or uncon-
trolled studies conducted before or during the initial phases
of HAART reported variable success with the use of
corticosteroids in patients with HIV-associated kidney
diseases.419–421 There is only one study using cyclosporine
in 15 children with HIV and nephrotic syndrome.422 These
early observational studies suggested a benefit for ACE-I and
corticosteroids in HIV-mediated kidney disease, but the
studies were prior to introduction of HAART, and in the era
of modern HAART therapy, it is unclear what the potential
benefits are, if any, of the use of corticosteroids or
cyclosporine in the treatment of patients with HIVAN or
other HIV-related kidney diseases. It is not known whether
this benefit remains in the context of current management.418
There is no RCT that evaluates the value of HAART
therapy in patients with HIVAN.423 There is very low–quality
evidence to suggest that HAART may be of benefit in patients
with HIV-associated immune-complex kidney diseases and
thrombotic microangiopathies.391,394,411 There are recent
comprehensive reviews of HIV and kidney disease that
describe current knowledge and gaps therein.424,425
RESEARCH RECOMMENDATIONS
K RCTs are needed to evaluate the efficacy of HAART in
HIVAN and other HIV-associated glomerular diseases.
Long-term follow-up is needed to determine if kidney
damage in susceptible individuals is halted or merely
slowed by HAART, particularly when control of viremia
is incomplete or intermittent.
K An RCT is needed to evaluate the role of corticosteroids
in combination with HAART in the treatment of HIV-
associated kidney diseases.
K An RCT is needed to determine if benefits of RAS
blockade are independent of HAART therapy in patients
with HIVAN and other HIV-mediated kidney diseases.
9.5: Schistosomal, filarial, and malarial nephropathies
9.5.1: We suggest that patients with GN and con-
comitant malarial, schistosomal, or filarial
infection be treated with an appropriate anti-
parasitic agent in sufficient dosage and duration
to eradicate the organism. (Not Graded)
Table 24 | The spectrum of kidney disease in HIV-infected
patients
K HIVAN-collapsing FSGS
K Arterionephrosclerosis
K Immune-complex GN
–MPGN pattern of injury
–Lupus-like GN
K Idiopathic FSGS
K HCV and cryoglobulinemia
K Thrombotic microangiopathies
K Membranous nephropathy
–HBV-mediated
–Malignancy
K Minimal-change nephropathy
K IgAN
K Diabetic nephropathy
K Postinfectious GN
–Infectious endocarditis
–Other infections: Candida, Cryptococcus
K Amyloidosis
K Chronic pyelonephritis
K Acute or chronic interstitial nephritis
K Crystal nephropathy
–Indinavir, atazanavir, i.v. acyclovir, sulfadiazine
K Acute tubular necrosis
K Proximal tubulopathy (Fanconi syndrome)
–Tenofovir
FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; HBV, hepatitis B
virus; HCV, hepatitis C virus; HIVAN, human immunodeficiency virus–associated
nephropathy; IgAN, immunoglobulin A nephropathy; MPGN, mesangial proliferative
glomerulonephritis.
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9.5.2: We suggest that corticosteroids or immuno-
suppressive agents not be used for treatment
of schistosomal-associated GN, since the GN is
believed to be the direct result of infection and
the attendant immune response to the organ-
ism. (2D)
9.5.3: We suggest that blood culture for Salmonella
be considered in all patients with hepato-
splenic schistosomiasis who show urinary
abnormalities and/or reduced GFR. (2C)
9.5.3.1: We suggest that all patients who show
a positive blood culture for Salmonella
receive anti-Salmonella therapy. (2C)
SCHISTOSOMAL NEPHROPATHY
BACKGROUND
Schistosomiasis (syn. Bilharziasis), a chronic infection by
trematodes (blood flukes), is encountered in Asia, Africa, and
South America.426,427 S. mansoni and S. japonicum cause
glomerular lesions in experimental studies, but clinical
glomerular disease has been described most frequently in
association with hepatosplenic schistosomiasis produced by
S. mansoni.428–436 A classification of schistosomal glomerulo-
pathies is given in Table 25. It should be recognized that, in
highly endemic areas, the association of GN with schistoso-
miasis may be coincidental rather than causal.
RATIONALE
The incidence of GN in schistosomiasis is not well defined.
Hospital-based studies have shown overt proteinuria in
1–10% and microalbuminuria in about 22% of patients with
hepatosplenic schistosomiasis due to S. mansoni.437,438 Sobh
et al.439 documented asymptomatic proteinuria in 20%
patients with ‘‘active’’ S. mansoni infection. A field study in
an endemic area of Brazil showed only a 1% incidence of
proteinuria.440 However, histological studies have documen-
ted glomerular lesions in 12 – 50% of cases.430,435
GN is most commonly seen in young adults, and males
are affected twice as frequently as females. In addition to
nephrotic syndrome, eosinophiluria is seen in 65% of cases
and hypergammaglobulinemia in 30%.441 Hypocomplemen-
temia is common. Several studies have shown new-onset
or worsening of nephrotic syndrome in the presence of
coinfection with Salmonella.442
Several patterns of glomerular pathology have been
described (see Table 25). Class I is the earliest and most
frequent lesion. Class II lesion is more frequent in patients
with concomitant Salmonella (S. typhi, S. paratyphi A, or
S. typhimurium) infection.443,444
Praziquantel, given in a dose of 20 mg/kg three times for 1
day, is effective in curing 60–90% patients with schisto-
somiasis. Oxamiquine is the only alternative for S. mansoni
infection.445 Successful treatment helps in amelioration of
hepatic fibrosis and can prevent development of glomerular
disease. Established schistosomal GN, however, does not
respond to any of these agents.
Steroids, cytotoxic agents, and cyclosporine are ineffective
in inducing remission.446 In one RCT, neither prednisolone
nor cyclosporine, given in combination with praziquantel
and oxamiquine were effective in inducing remissions in
patients with established schistosomal GN.447
Treatment of coexistent Salmonella infection favorably
influences the course of GN. In a study of 190 patients with
schistosomiasis, 130 were coinfected with Salmonella. All of
them showed improvement in serum complement levels,
CrCl, and proteinuria following antibilharzial and anti-
Salmonella treatment, either together or sequentially.448
Other studies have shown disappearance of urinary abnorm-
alities following anti-Salmonella therapy alone.442,444 The
prognosis is relatively good with class I and II schistosomal
GN, provided sustained eradication of Schistosoma and
Salmonella infection can be achieved, whereas class IV and
V lesions usually progress to ESRD despite treat-
ment.446,449,450 The association of Salmonella infection with
schistosomal GN is not observed in all geographical areas.451
Table 25 | A clinicopathological classification of schistosomal glomerulopathy
Class Light-microscopic pattern Immunofluorescence
Asymptomatic
proteinuria
Nephrotic
syndrome
Hyper-
tension
Progression
to ESRD
Response to
treatment
I Mesangio-proliferative
Minimal lesion
Focal proliferative
Diffuse proliferative
Mesangial IgM, C3, schistosomal
gut antigens
+++ + +/ ? +/
II Exudative Endocapillary C3, schistosomal antigens  +++  ? +++
III A. Mesangio-capillary
type I
Mesangial IgG, C3, schistosomal gut
antigen (early), IgA (late)
+ ++ ++ ++ 
B. Mesangio-capillary
type II
Mesangial and subepithelial IgG, C3,
schistosomal gut antigen (early), IgA (late)
+ +++ + ++ 
IV Focal and segmental
glomerulo-sclerosis
Mesangial IgG, IgM, IgA + +++ +++ +++ 
V Amyloidosis Mesangial IgG + +++ +/ +++ 
ESRD, end-stage renal disease.
Adapted by permission from Macmillan Publishers Ltd: Kidney International. Barsoum RS. Schistosomal glomerulopathies. Kidney Int 1993; 44: 1–12;437 accessed
http://www.nature.com/ki/journal/v44/n1/pdf/ki1993205a.pdf.
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RESEARCH RECOMMENDATION
K Studies are required to evaluate the precise contribution
of Salmonella infection to schistosomal nephropathy, and
the value of treating these two infections separately or
together on the outcome.
FILARIAL NEPHROPATHY
BACKGROUND AND RATIONALE
Filarial worms are nematodes that are transmitted to humans
through arthropod bites, and dwell in the subcutaneous
tissues and lymphatics. Clinical manifestations depend upon
the location of microfilariae and adult worms in the tissues.
Of the eight filarial species that infect humans, glomerular
disease has been reported in association with Loa loa,
Onchocerca volvulus, Wuchereria bancrofti, and Brugia malayi
infections in Africa and some Asian countries.452–456
Glomerular involvement is seen in a small number of
cases. Light microscopy reveals a gamut of lesions, including
diffuse GN and MPGN, membranoproliferative GN, mini-
mal-change and chronic sclerosing GN, and the collapsing
variant of FSGS.457 Microfilariae may be found in the
arterioles, glomerular and peritubular capillary lumina,
tubules, and interstitium.457 Immunofluorescence and elec-
tron microscopy show immune deposits along with worm
antigens and structural components.456,458
Urinary abnormalities have been reported in 11–25% and
nephrotic syndrome is seen in 3–5% of patients with loiasis and
onchocerciasis, especially those with polyarthritis and chorior-
etinitis.456,459 Proteinuria and/or hematuria was detected in over
50% of cases with lymphatic filariasis; 25% showed glomerular
proteinuria.460,461 A good response (diminution of proteinuria)
is observed following antifilarial therapy in patients with non-
nephrotic proteinuria and/or hematuria. The proteinuria can
increase and kidney functions worsen following initiation of
diethylcarbamazepine or ivermectin,461,462 probably because of
an exacerbation of the immune process secondary to antigen
release into circulation after death of the parasite.463
The response is inconsistent in those with nephrotic
syndrome, and deterioration of kidney function may
continue, despite clearance of microfilariae with treatment.
Therapeutic apheresis has been utilized to reduce the
microfilarial load before starting diethylcarbamazepine to
prevent antigen release.464
The incidence, prevalence, and natural history of glomer-
ular involvement in various forms of filariasis are poorly
documented. This condition is usually found in areas with
poor vector control and inadequate health-care facilities.
Similarly, the treatment strategies have not been evaluated.
RESEARCH RECOMMENDATION
K Epidemiological studies of kidney involvement in
regions endemic for these conditions are required. The
effect of population-based treatment with fila-
ricidal agents on the course of kidney disease should
be studied.
MALARIAL NEPHROPATHY
BACKGROUND AND RATIONALE
Infection with Plasmodium falciparum usually results in AKI
or proliferative GN. Chronic infection with the protozoal
malarial parasites Plasmodium malariae (and, to a lesser extent,
Plasmodium vivax or ovale) has been associated with a variety
of kidney lesions, including MN and membranoproliferative
GN.465 In the past, this has been known as ‘‘quartan malarial
nephropathy’’.465,466 Nephrotic syndrome, sometimes with
impaired kidney function, is a common clinical manifestation;
it is principally encountered in young children. The glomerular
lesions are believed to be caused by deposition of immune
complexes containing antigens of the parasite, but autoimmu-
nity may participate as well. The clinical and morphological
manifestations vary from country to country.467 Nowadays, the
lesion is much less common, and most children in the tropics
with nephrotic syndrome have either MCD or FSGS, rather
than malarial nephropathy.467,468 HBV and HIV infection and
streptococcal-related diseases are also now more common
causes of nephrotic syndrome than malarial nephropathy
in Africa.467–469
There are limited observational studies and no RCTs for an
evidence-based treatment strategy for malarial nephropathy.
Patients with GN and concomitant infection with Plasmodium
species (typically Plasmodium malariae) should be treated with
an appropriate antimalarial agent (such as chloroquine or
hydroxychloroquine) for suffcient duration to eradicate the
organism from blood and hepatosplenic sites. Observational
studies have suggested improvement in clinical manifestations
in some—but not all—patients, following successful eradica-
tion of the parasitic infection. There does not appear to be any
role for steroids or immunosuppressant therapy in mala-
rial nephropathy,465,466 although controlled trials are lacking.
Dosage reductions of chloroquine or hydroxychloroquine may
be needed in patients with impaired kidney function.
RESEARCH RECOMMENDATIONS
K Studies of the incidence and prevalence of malarial
nephropathy, and its response to antimalarial therapy are
needed, especially in endemic areas of West Africa.
K RCTs are needed to investigate the role of corticosteroids
and immunosuppressive agents when malarial nephro-
pathy progresses, despite eradication of the malarial
parasite.
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